227 related articles for article (PubMed ID: 27515689)
1. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.
Kerns SL; Dorling L; Fachal L; Bentzen S; Pharoah PD; Barnes DR; Gómez-Caamaño A; Carballo AM; Dearnaley DP; Peleteiro P; Gulliford SL; Hall E; Michailidou K; Carracedo Á; Sia M; Stock R; Stone NN; Sydes MR; Tyrer JP; Ahmed S; Parliament M; Ostrer H; Rosenstein BS; Vega A; Burnet NG; Dunning AM; Barnett GC; West CM;
EBioMedicine; 2016 Aug; 10():150-63. PubMed ID: 27515689
[TBL] [Abstract][Full Text] [Related]
2. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen CN; Rosenstein BS; Kerns SL; Ostrer H; De Ruysscher D; Cesaretti JA; Barnett GC; Dunning AM; Dorling L; West CML; Burnet NG; Elliott R; Coles C; Hall E; Fachal L; Vega A; Gómez-Caamaño A; Talbot CJ; Symonds RP; De Ruyck K; Thierens H; Ost P; Chang-Claude J; Seibold P; Popanda O; Overgaard M; Dearnaley D; Sydes MR; Azria D; Koch CA; Parliament M; Blackshaw M; Sia M; Fuentes-Raspall MJ; Ramon Y Cajal T; Barnadas A; Vesprini D; Gutiérrez-Enríquez S; Mollà M; Díez O; Yarnold JR; Overgaard J; Bentzen SM; Alsner J;
Radiother Oncol; 2016 Dec; 121(3):431-439. PubMed ID: 27443449
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.
Kerns SL; Stock RG; Stone NN; Blacksburg SR; Rath L; Vega A; Fachal L; Gómez-Caamaño A; De Ruysscher D; Lammering G; Parliament M; Blackshaw M; Sia M; Cesaretti J; Terk M; Hixson R; Rosenstein BS; Ostrer H
Radiother Oncol; 2013 Jun; 107(3):372-6. PubMed ID: 23719583
[TBL] [Abstract][Full Text] [Related]
4. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
Kerns SL; Fachal L; Dorling L; Barnett GC; Baran A; Peterson DR; Hollenberg M; Hao K; Narzo AD; Ahsen ME; Pandey G; Bentzen SM; Janelsins M; Elliott RM; Pharoah PDP; Burnet NG; Dearnaley DP; Gulliford SL; Hall E; Sydes MR; Aguado-Barrera ME; Gómez-Caamaño A; Carballo AM; Peleteiro P; Lobato-Busto R; Stock R; Stone NN; Ostrer H; Usmani N; Singhal S; Tsuji H; Imai T; Saito S; Eeles R; DeRuyck K; Parliament M; Dunning AM; Vega A; Rosenstein BS; West CML
J Natl Cancer Inst; 2020 Feb; 112(2):179-190. PubMed ID: 31095341
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Renner W; Gerger A; Kapp KS; Langsenlehner T
Strahlenther Onkol; 2014 Mar; 190(3):304-9. PubMed ID: 24424626
[TBL] [Abstract][Full Text] [Related]
6. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
Barnett GC; Thompson D; Fachal L; Kerns S; Talbot C; Elliott RM; Dorling L; Coles CE; Dearnaley DP; Rosenstein BS; Vega A; Symonds P; Yarnold J; Baynes C; Michailidou K; Dennis J; Tyrer JP; Wilkinson JS; Gómez-Caamaño A; Tanteles GA; Platte R; Mayes R; Conroy D; Maranian M; Luccarini C; Gulliford SL; Sydes MR; Hall E; Haviland J; Misra V; Titley J; Bentzen SM; Pharoah PD; Burnet NG; Dunning AM; West CM
Radiother Oncol; 2014 May; 111(2):178-85. PubMed ID: 24785509
[TBL] [Abstract][Full Text] [Related]
7. Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Ahmed M; Dorling L; Kerns S; Fachal L; Elliott R; Partliament M; Rosenstein BS; Vega A; Gómez-Caamaño A; Barnett G; Dearnaley DP; Hall E; Sydes M; Burnet N; Pharoah PD; Eeles R; West CM
Br J Cancer; 2016 May; 114(10):1165-74. PubMed ID: 27070714
[TBL] [Abstract][Full Text] [Related]
8. Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.
Dorling L; Barnett GC; Michailidou K; Coles CE; Burnet NG; Yarnold J; Elliott RM; Dunning AM; Pharoah PD; West CM
Clin Cancer Res; 2016 Mar; 22(6):1413-20. PubMed ID: 26510858
[TBL] [Abstract][Full Text] [Related]
9. No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
Barnett GC; Kerns SL; Dorling L; Fachal L; Aguado-Barrera ME; Martínez-Calvo L; Jandu HK; Welsh C; Tyrer J; Coles CE; Haviland JS; Parker C; Gómez-Caamaño A; Calvo-Crespo P; Sosa-Fajardo P; Burnet NG; Summersgill H; Webb A; De Ruysscher D; Seibold P; Chang-Claude J; Talbot CJ; Rattay T; Parliament M; De Ruyck K; Rosenstein BS; Pharoah PDP; Dunning AM; Vega A; West CML;
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):494-501. PubMed ID: 35840111
[TBL] [Abstract][Full Text] [Related]
10. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.
Kerns SL; Stone NN; Stock RG; Rath L; Ostrer H; Rosenstein BS
J Urol; 2013 Jul; 190(1):102-8. PubMed ID: 23376709
[TBL] [Abstract][Full Text] [Related]
11. XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients.
Seibold P; Behrens S; Schmezer P; Helmbold I; Barnett G; Coles C; Yarnold J; Talbot CJ; Imai T; Azria D; Koch CA; Dunning AM; Burnet N; Bliss JM; Symonds RP; Rattay T; Suga T; Kerns SL; Bourgier C; Vallis KA; Sautter-Bihl ML; Claßen J; Debus J; Schnabel T; Rosenstein BS; Wenz F; West CM; Popanda O; Chang-Claude J
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1084-1092. PubMed ID: 26072091
[TBL] [Abstract][Full Text] [Related]
12. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
Barnett GC; Coles CE; Elliott RM; Baynes C; Luccarini C; Conroy D; Wilkinson JS; Tyrer J; Misra V; Platte R; Gulliford SL; Sydes MR; Hall E; Bentzen SM; Dearnaley DP; Burnet NG; Pharoah PD; Dunning AM; West CM
Lancet Oncol; 2012 Jan; 13(1):65-77. PubMed ID: 22169268
[TBL] [Abstract][Full Text] [Related]
13. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
[TBL] [Abstract][Full Text] [Related]
14. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; Seibold P; West C; Janelsins M; Chen Y; Messing E; Morrow G;
Radiother Oncol; 2022 Mar; 168():75-82. PubMed ID: 35077710
[TBL] [Abstract][Full Text] [Related]
15. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.
Fachal L; Gómez-Caamaño A; Barnett GC; Peleteiro P; Carballo AM; Calvo-Crespo P; Kerns SL; Sánchez-García M; Lobato-Busto R; Dorling L; Elliott RM; Dearnaley DP; Sydes MR; Hall E; Burnet NG; Carracedo Á; Rosenstein BS; West CM; Dunning AM; Vega A
Nat Genet; 2014 Aug; 46(8):891-4. PubMed ID: 24974847
[TBL] [Abstract][Full Text] [Related]
16. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.
Damaraju S; Murray D; Dufour J; Carandang D; Myrehaug S; Fallone G; Field C; Greiner R; Hanson J; Cass CE; Parliament M
Clin Cancer Res; 2006 Apr; 12(8):2545-54. PubMed ID: 16638864
[TBL] [Abstract][Full Text] [Related]
17. Finding the genetic determinants of adverse reactions to radiotherapy.
Rattay T; Talbot CJ
Clin Oncol (R Coll Radiol); 2014 May; 26(5):301-8. PubMed ID: 24702740
[TBL] [Abstract][Full Text] [Related]
18. Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.
Franco NR; Massi MC; Ieva F; Manzoni A; Paganoni AM; Zunino P; Veldeman L; Ost P; Fonteyne V; Talbot CJ; Rattay T; Webb A; Johnson K; Lambrecht M; Haustermans K; De Meerleer G; de Ruysscher D; Vanneste B; Van Limbergen E; Choudhury A; Elliott RM; Sperk E; Veldwijk MR; Herskind C; Avuzzi B; Noris Chiorda B; Valdagni R; Azria D; Farcy-Jacquet MP; Brengues M; Rosenstein BS; Stock RG; Vega A; Aguado-Barrera ME; Sosa-Fajardo P; Dunning AM; Fachal L; Kerns SL; Payne D; Chang-Claude J; Seibold P; West CML; Rancati T;
Radiother Oncol; 2021 Jun; 159():241-248. PubMed ID: 33838170
[TBL] [Abstract][Full Text] [Related]
19. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer.
Kerns SL; Stock R; Stone N; Buckstein M; Shao Y; Campbell C; Rath L; De Ruysscher D; Lammering G; Hixson R; Cesaretti J; Terk M; Ostrer H; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e21-8. PubMed ID: 23021708
[TBL] [Abstract][Full Text] [Related]
20. Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients.
Schack LMH; Petersen SE; Nielsen S; Lundby L; Høyer M; Bentzen L; Overgaard J; Andreassen CN; Alsner J
Acta Oncol; 2017 Nov; 56(11):1514-1521. PubMed ID: 28844157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
